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Background: Up to 7% of all adrenal incidentalomas (AI ) are pheochromocytomas (PCCs). 
In the evaluation of AI, it is generally recommended to exclude PCC by measurement plasma 
free or 24h urinary fractionated metanephrines. However, recent studies suggest to abstain 
from biochemical exclusion of PCC in cases of lesion  with computed tomography (CT) 
characteristics of an adrenocortical adenoma (ACA).                   
Aim: To determine the proportion of PCCs with ACA-like attenuation or contrast washout on 
CT.  
Methods: For this multicenter retrospective study, two central investigators independently 
analyzed the CT reports of 533 patients with 548 histologically confirmed PCCs. Data on 
tumor size, unenhanced Hounsfield Units (HU), absolute percentage washout (APW) and 
relative percentage washout (RPW) were collected besides clinical parameters.  
Results: Among the 376 PCCs for which unenhanced att nuation data were available, 374 
had an attenuation of >10 HU (99.5%). In the two exceptions (0,5%), unenhanced attenuation 
was exactly 10 HU, which lies just within the range of ≤10 HU that would suggest a 
diagnosis of ACA. Of 76 PCCs with unenhanced HU >10and available washout data, 22 
(28,9%) had a high APW and/or RPW, suggestive of ACA.  
Conclusion: Based on the lack of PCCs with an unenhanced attenuation of <10 HU, and the 
low proportion (0,5%) of PCCs with an attenuation of =10 HU, it seems reasonable to abstain 
from biochemical testing for PCC in AIs with an unenhanced attenuation ≤10 HU. The 
assessment of contrast washout, however, is unreliabl  to rule out PCC.    
This retrospective study examines the CT characteristics of 548 pheochromocytomas (PCCs). The 
findings suggest to avoid biochemical testing for PCC in incidentalomas with unenhanced attenuation 
≤10HU. 
Introduction 
Adrenal pheochromocytomas (PCCs) and extra-adrenal sympathetic paragangliomas are rare 
tumors that arise from catecholamine producing chromaffin cells 1. Up to 40% of chromaffin 
tumors are associated with hereditable tumor syndromes 2-5. The most accurate diagnostic test 
for the biochemical diagnosis of these tumors is the measurement of plasma free or 24h 
urinary fractionated metanephrines 6,7. Typical symptoms and signs include headache, 
tremors, palpitations, sweating, and anxiety. However, in up to 25% of patients signs and 
symptoms are lacking and up to 30% of PCCs are diagnosed following the discovery of an 
adrenal incidentaloma (AI) 7,8. 
The prevalence of AI on thoracic, abdominal and pelvic computed tomography (CT) 
ranges between 1.0% and 8.7% depending on age 9-14. The majority of AIs are adrenocortical 
adenoma (ACA) 12. Less prevalent causes are myelolipomas, cysts, adrenocortical carcinoma 
and metastases from other malignancies. PCCs account for up to 7% of AIs 7. In contrast to 
situations when significant adrenal hormone secretion or malignancy are suspected, no 
treatment is indicated for benign non-functioning ACA. In 2016, the European Society of 
Endocrinology (ESE) in collaboration with the European Network for the Study of Adrenal 
Tumors (ENSAT) published a guideline to provide clini ians with evidence-based 
recommendations for clinical management of patients with AIs 7. This guideline adapts a 
generally accepted approach in the evaluation of AI by taking into account quantitative CT 
characteristics. Either an attenuation of ≤10 Hounsfield Units (HU) on an unenhanced CT, or 









































































The Journal of Clinical Endocrinology & Metabolism; Copyright 2018  DOI: 10.1210/jc.2018-01532 
 
 3
on a CT with delayed washout after 10-15 min are considered suggestive of ACA. However, 
the guidelines and an accompanied meta-analysis 15 clearly indicated that the unenhanced CT 
is the only reliable method to differentiate benign from malignant adrenal tumors. In addition, 
it was recommended to perform an endocrine work-up for AI, including the measurement of 
plasma free or 24h urinary fractionated metanephrines. However, it was also discussed that it 
could be reasonable to avoid biochemical testing for PCC in patients AI with a unenhanced 
attenuation of ≤10 HU. Nevertheless, the authors acknowledged that only two small studies 
were published on this topic 16,17. The findings in the latter studies require confirmation in a 
larger number of patients before substantiated statements can be made. It is important to note 
that PCCs demonstrating an attenuation ≤10 HU have been described in literature, though 
very uncommonly 18,19. Hence, in this international multicenter study we retrospectively 
evaluated the quantitative CT characteristics of PCCs, as indicated in the radiological reports, 
to assess the proportion and associated characteristi s of PCCs with an ACA-like attenuation 




We included patients with a histologically proven PCC (single or multiple) who had 
undergone a pre-operative CT scan, i.e. either unenhanced CT (+/- contrast enhanced CT) or 
contrast washout CT. Patients with post-contrast CT scan only were not eligible for inclusion. 
Patients had been diagnosed and treated in centers affiliated to ENSAT. Participating ENSAT 
centers were Mayo Clinic (n=153), Rochester, USA; Radboud University Medical Center, 
Nijmegen, The Netherlands (n=46); University Hospital Center Zagreb, Zagreb, Croatia 
(n=43); Carol Davila University of Medicine and Pharm cy, Bucharest, Romania (n=42); 
Medical University of Warsaw, Warsaw, Poland (n=33); CHU de Bordeaux, Pessac, France 
(n=29); University Medical Center Groningen, Groninge , The Netherlands (n= 28); 
University Hospital of Florence, Florence, Italy (n=21); University of Birmingham, 
Birmingham, United Kingdom (n=20); Center hospitalier de l'Université de Montréal, 
Montreal, Canada (n=19); Hospices Civils de Lyon, Lyon, France (n=17); University 
Hospital of Wuerzburg, Wuerzburg, Germany (n=17); University Hospital of Krakow, 
Krakow, Poland (n=16); Cambridge University Hospitals, Cambridge, United Kingdom 
(n=12); Endocrinology in Charlottenburg, Berlin, Germany (n=12); Center Hospitalier  
Universitaire de Liege, Liege, Belgium (n=10); Medizin sche Klinik und Poliklinik IV 
Ludwig-Maximilians-Universität München, Munich, Germany (n=10); Hospital General 
Universitario de Albacete, Albacete, Spain (n=5). Patients provided informed consent, either 
under ENSAT or local institutional protocol, when required. Two hundred fourteen patients 
from the two Dutch centers were also included in a previous study on this topic by 
Buitenwerf et al.20. In the latter study, a central re-evaluation of CT images was performed to 
calculate unenhanced attenuation, whereas in the curr nt study, both unenhanced attenuation 
and contrast washout were analyzed based on locally generated CT reports. Additional 
inclusion criteria were age at diagnosis >18 years, a diagnosis in or after the year 2000, 
availability of the CT report and clinical annotations (age, sex, underlying hereditary 
syndrome).  
Biochemical testing and imaging 
Biochemical testing, usually by measurement of plasma free or 24h urinary fractionated 
metanephrines, was performed according to local protocols with corresponding reference 
values. If metanephrines were not available, 24h urine or plasma catecholamines were 
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“noradrenergic” or “normal”. The phenotype was classified as “adrenergic” when the 
increment of metanephrines, relative to the upper limits of normal, exceeded 5% of the 
combined metanephrine and normetanephrine increments. Pa ients in whom these criteria 
were not fulfilled and in whom normetanephrine leves exceeded the upper limits of normal 
were classified as “noradrenergic” 21. In addition, CT scans were performed according to 
local protocols regarding contrast procedure, acquisition and reconstruction parameters and 
approach to draw the region of interest for HU measurements.  
Evaluation of CT reports 
Anonymized imaging reports of pre-operative CT scan, generated by local radiologists as 
part of routine diagnostic evaluation, were submitted for central analysis. The reports were 
evaluated and scored independently by two observers (LC; JVH) who were blinded to the 
clinical information. Type of CT scan and field of view, number and location of lesions, 
tumor size, unenhanced HU, APW and RPW were considered. In case multiple unenhanced 
HU values were mentioned, the highest value was choen for analysis. When in the local 
report values for APW/RPW were not mentioned, APW and RPW were calculated according 
to the formulas below, provided that the required parameters were available. 
 
     
APW  1 00%
     
HU portal venous phase HU delayed phase
x





     
RPW  1 00%
   
HU portal venous phase HU delayed phase
x
HU portal venous phase
−=
 
PCCs were classified as ACA-like based on quantitative CT characteristics in case one of the 
following criteria were fulfilled: 1. Attenuation on unenhanced CT <10 HU or 2. Attenuation 
on unenhanced CT >10 HU and APW ≥60% and/or RPW ≥40%.  
Data management and statistical analysis 
Statistical analysis was performed with SPSS 17.0 for Windows. Clinical characteristics were 
compared between PCC patients with and without an ACA-like attenuation based on 
quantitative criteria. Characteristics were compared using an unpaired T test if variables were 
continuous or a Chi square test if variables were cat gorical. A two-sided P value of <0.05 
was considered statistically significant.   
Results 
In total, 1011 cases of PCCs and extra adrenal sympathetic paragangliomas were screened for 
eligibility by the local investigators at the 18 participating centers. Four hundred and seven 
cases were excluded, mainly because of the performance of post-contrast CT only (n=305). 
After central review, 71 additional cases were excluded based on a diagnosis of extra-adrenal 
paraganglioma rather than PCC (n=25), lack of CT report (n=21), incomplete CT report 
(n=14), age <18 years (n=5), lack of histological proof of PCC (n=4) and performance of 
post-contrast CT only (n=2). Out of the remaining 533 patients with 548 histologically 
confirmed PCCs, quantitative CT characteristics were available in 368 patients with 382 
PCCs (376 unenhanced HU +/- washout and 6 washout only). The clinical characteristics and 
information regarding HU and maximun diameter of PCCs are given in Table 1. The 
distribution of unenhanced attenuation (HU) is repoted in Figure 1. Details on CT scan 
protocols and availability of quantitative data from radiology reports are given in Table 2. 
PCCs with ACA-like attenuation or washout  
Among the 376 PCCs for which unenhanced attenuation was available, 374 had an 
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attenuation was exactly 10 HU, which lies just within the range of ≤10 HU that would 
suggest a diagnosis of ACA (supplemental Table 1 22). Of these two PCCs, the histology 
reports were re-evaluated. The first lesion was a 42 mm right adrenal PCC with extensive 
central haemorrhage. Pre-operative urine catecholamine values were reported to be in the 
normal range, however, metanephrines were not measur d. The second lesion was a 48 mm 
left adrenal PCC contained areas of prominent nodular adrenocortical hyperplasia besides 
PCC. No information on the biochemical phenotype could be retrieved.  
Of 76 PCCs with unenhanced HU >10 and available washout, 22 (28,9%) had an APW 
≥60% and/or an RPW ≥40%, suggestive of ACA. In one additional PCC APW/RPW was 
high as well, but unenhanced attenuation was unavailable. The local radiologists reported on 
six additional lesions with characteristics of ACA. The reasons for this, however, could not 
be verified, since washout data were unavailable and in the two cases where unenhanced 
attenuation was mentioned, it was >10 HU.  
The PCCs with an unenhanced attenuation of >10 HU and high APW and/or RPW (n=22) 
did not differ from those with an unenhanced attenuation of >10 HU and low washout (n=54) 
with respect to sex, tumor size and hereditary syndrome (data not shown). 
Two hundred eighty-two out of 548 PCCs (51.4%) were initially discovered as AI in 276 
patients. One out of 199 lesions (lesion 1 in supplemental Table 1) with available quantitative 
data was among the two lesions of 10 HU. In this subgroup, out of 29 PCCs with unenhanced 
HU >10 and available washout, 10 (34.4%) had a highAPW and/or RPW. 
Discussion 
We retrospectively evaluated the CT characteristics of PCC in the largest international cohort 
to date. Our main goal was to determine the proportion of PCCs with an ACA-like 
appearance based on either a low unenhanced attenuation or a high contrast washout. The 
analysis was based on locally generated radiological reports. Unenhanced HU values were 
available for 376 out of 548 histologically confirmed PCCs, two of which (0,5%) exhibited 
an attenuation of exactly 10 HU, consistent with an ACA-like attenuation according to recent 
ESE/ENS@T guidelines. In addition, among 76 PCCs with unenhanced HU >10 and 
available washout, 22 (28,9%) showed a high APW and/or RPW, wrongfully suggestive of 
ACA.   
In 2016 ESE/ENSAT provided clinical practice guideln s for the management of patients 
affected by AIs. It was recommended that, as part of the endocrine workup, PCC should be 
excluded by measurement of plasma free or 24h urinary fr ctionated metanephrines in all 
AIs. However, it was discussed that an exception could be made for those cases where a non-
contrast-enhanced CT attenuation was ≤10 HU. A disclaimer was made that the evidence to 
support this exception was very low, referring to tw  studies that showed a low likelihood of 
a PCC among adrenal lesions that are radiologically suggestive of ACA 16,17. Sane et al. 16 
examined whether PCC could be ruled out as cause of AIs on the basis of unenhanced 
attenuation values only. A cohort of 174 patients with AI was evaluated retrospectively. 
Unenhanced attenuation was available for 115 tumors. Nine patients had a PCC and in none 
of these tumors the unenhanced HU was below 10. They concluded that routine measurement 
of metanephrines is unnecessary in an asymptomatic p tient with AI, provided that the lesion 
is of low attenuation, small and homogenous.  Schalin-Jantti et al. 17 performed a 5-year 
prospective follow-up study of 56 patients with 69 lipid-rich (i.e. low attenuation) AIs, 
showing that 24h urinary metanephrines were normal at baseline as well as during follow-up. 
In addition, Jun et al. 19 studied 251 patients with AI and had similar results, leading to the 
conclusion that for small lesions (AI size <3 cm) non-contrast CT can substitute for 
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in these previous studies are based on small subsets of PCCs among cohorts of patients with 
AIs.  
Rather than taking AI as a starting point, in the pr sent study and in one previous report, 
primarily patients with PCC were selected. Buitenwerf et al. 20 recently conducted a 
retrospective study including 214 patients affected by 222 histologically proven PCCs. Two 
expert radiologists re-evaluated the CT scan images independently. Only one PCC out of 222 
demonstrated an attenuation value of <10 HU. This wa a rare case of ACTH-dependent 
Cushing disease caused by a PCC. In the current study we found a similarly low proportion 
(0,5%) of PCCs with an unenhanced attenuation of ≤10 HU. In fact in none of the PCCs the 
unenhanced attenuation was below 10 HU and in only two PCCs it was exactly 10 HU. In 
these two cases, histology possibly provided some explanation. Hemorrhage, necrosis and 
additional adrenocortical 23 changes may result in intralesional heterogeneity, mphasizing 
the importance of selecting the proper region of interest for the assessment of attenuation.  
In ~70% of AIs attenuation values are ≤10 HU, illustrating the large number of patients 
that might benefit from implementing radiological se ection to determine in which patients 
biochemical screening is needed as second line test to rule out PCC 15.  Approximately 2000 
patients with adrenal incidentaloma and attenuation value ≤10 HU would need to be 
biochemically screened in order to diagnose one casof PCC, assuming a 7% prevalence of 
PCC in the AI population, 70% frequency of attenuation ≤10 HU and a false-negative rate of 
0.5% of radiological classification as determined in the present study (2857 AIs in total, 
including 2000 AIs ≤10 HU (70% of 2857) and 200 PCCs (7% of 2857), of which 1 (0.5% of 
200) is missclassified by CT). In our opinion, this observation justifies omitting biochemical 
screening in low-attenuation AIs in order to prevent false-positive test results and 
unnecessary costs. In the given example of 2000 low attenuation AIs, based on 50 USD costs 
of metanephines measurement, omitting biochemical testing would result in an immediate 
cost reduction of  100.000 USD. In the context of aspecificity of plasma metanephrines of 
~80-90% 1, the true cost reduction is expected to be (much) higher when taking into account 
follow-up investigations prompted by false-positive biochemical testing results that could 
have been prevented.  
Besides unenhanced HU, contrast washout rates are routinely used for the evaluation of 
adrenal lesions. The majority of ACA with an unenhaced HU >10 exhibit a high washout. 
Conversely, a high washout does not rule out PCC. We found that in almost one third of 
PCCs with available APW/RPW data, washout was high. This is in line with a previously 
meta-analysis of ten studies by Woo et al. 24. They reported a rate of PCCs with a high 
washout pattern of 35%. Washout data for AI should therefore not be used to determine 
whether biochemical testing should be done or not. 
There are several limitations to this study. This is a retrospective study of locally 
generated radiology reports coming from different centers using different CT machines, 
settings and contrast protocols. Drawing of the region of interest for the calculation of 
radiodensity was done at the discretion of the local radiologist. The impact of these potential 
confounders, however, is probably limited, inducing minimal variations in attenuation, 
estimated at 1-2 HU 20, 25. In addition, many cases were excluded because of the availability 
of post-contrast CT scans only. The detail to which different quantitative parameters were 
reported varied considerably, leading to many missing data. On the other hand, the data were 
extracted directly from clinical practice, representative for ‘real life’.    
Conclusion 
Based on the lack of PCCs with an unenhanced attenutio  of <10 HU, and the low 









































































The Journal of Clinical Endocrinology & Metabolism; Copyright 2018  DOI: 10.1210/jc.2018-01532 
 
 7
from biochemical testing for PCC in AIs with an unenhanced attenuation ≤10 HU. The 
assessment of contrast washout, however, is unreliabl  to rule out PCC. 
Acknowledgments 
We thank professor Jacques W.M. Lenders for his critical appraisal of the manuscript. 
Correspondence: Henri J.L.M. Timmers, Dep. of Interal Medicine, section 
Endocrinology (471), Radboud University Nijmegen Medical Center, PO Box 9101, 
6500 HB Nijmegen, the Netherlands, T +31 243614599, F +31 243614599, Email 
henri.timmers@radboudumc.nl 
The author reports no conflicts of interest in this work. 
Notes 
Abbreviations: ACA, adenoma; Ais, adrenal incidentalomas; APW, absolute percentage washout; CT, 
computed tomography; CTTA, CT texture analysis; ESE, European Society of Endocrinology; HU, 
Hounsfield units; lp-ACA, lipid-poor adenoma; MRI magnetic resonance imaging; PCCs, 
pheochromocytomas; RPW, relative percentage washout.  
References 
1. Lenders JWM, Duh QY, Eisenhofer G, l Gimenez-Roqueplo AP, Grebe SK, Murad 
MH, Naruse M, Pacak K, Young WF Jr; Endocrine Society. Pheochromocytoma and 
Paraganglioma: An Endocrine Society Clinical Practice Guideline. Journal of Clinical 
Endocrinology & Metabolism. 2014;99(6):1915-1942. 
2. Berends AMA, Buitenwerf E, de Krijger RR, Veeger NJGM, van der Horst-Schrivers 
ANA, Links TP, Kerstens MN. Incidence of pheochromocyt ma and sympathetic 
paraganglioma in the Netherlands: A nationwide study and systematic review. Eur J Intern 
Med. 2018;51:68-73. 
3. Dahia PL, Hao K, Rogus J, Colin C, Pujana MA, Ross K, Magoffin D, Aronin N, 
Cascon A, Hayashida CY, Li C, Toledo SP, Stiles CD;Familial Pheochromocytoma 
Consortium. Novel pheochromocytoma susceptibility loci identified by integrative genomics. 
Cancer Res. 2005;65(21):9651-9658. 
4. Vicha A, Musil Z, Pacak K. Genetics of pheochromocytoma and paraganglioma 
syndromes: new advances and future treatment options. Curr Opin Endocrinol Diabetes 
Obes. 2013;20(3):186-191. 
5. Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and phaeochromocytoma: 
from genetics to personalized medicine. Nat Rev Endocrinol. 2015;11(2):101-111. 
6. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 
2005;366(9486):665-675. 
7. Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, Tabarin A, 
Terzolo M, Tsagarakis S, Dekkers OM. Management of adrenal incidentalomas: European 
Society of Endocrinology Clinical Practice Guidelin in collaboration with the European 
Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175(2):G1-g34. 
8. Kopetschke R, Slisko M, Kilisli A, Tuschy U, Wall schofski H, Fassnacht M, Ventz 
M, Beuschlein F, Reincke M, Reisch N, Quinkler M. Frequent incidental discovery of 
phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J 
Endocrinol. 2009;161(2):355-361. 
9. Arnold DT, Reed JB, Burt K. Evaluation and management of the incidental adrenal 
mass. Proc (Bayl Univ Med Cent). 2003;16(1):7-12. 
10. Zeiger MA, Siegelman SS, Hamrahian AH. Medical and surgical evaluation and 









































































The Journal of Clinical Endocrinology & Metabolism; Copyright 2018  DOI: 10.1210/jc.2018-01532 
 
 8
11. Terzolo M, Bovio S, Pia A, Reimondo G, Angeli A. Management of adrenal 
incidentaloma. Best Pract Res Clin Endocrinol Metab. 2009;23(2):233-243. 
12. Young WF, Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J 
Med. 2007;356(6):601-610. 
13. Bulow B, Ahren B. Adrenal incidentaloma--experience of a standardized diagnostic 
programme in the Swedish prospective study. J Intern Med. 2002;252(3):239-246. 
14. Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of 
adrenal incidentalomas. Eur J Endocrinol. 2003;149(4):273-285. 
15. Dinnes J, Bancos I, Ferrante di Ruffano L, Chortis V, Davenport C, Bayliss S, Sahdev 
A, Guest P, Fassnacht M, Deeks JJ, Arlt W. MANAGEMENT OF ENDOCRINE DISEASE: 
Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a 
systematic review and meta-analysis. Eur J Endocrinol. 2016;175(2):R51-64. 
16. Sane T, Schalin-Jantti C, Raade M. Is biochemical s reening for pheochromocytoma 
in adrenal incidentalomas expressing low unenhanced att nuation on computed tomography 
necessary? J Clin Endocrinol Metab. 2012;97(6):2077-2083. 
17. Schalin-Jantti C, Raade M, Hamalainen E, Sane T. A 5-Year Prospective Follow-Up 
Study of Lipid-Rich Adrenal Incidentalomas: No Tumor Growth or Development of 
Hormonal Hypersecretion. Endocrinol Metab (Seoul). 2015;30(4):481-487. 
18. Blake MA, Krishnamoorthy SK, Boland GW, Sweeney AT, Pitman MB, Harisinghani 
M, Mueller PR, Hahn PF. Low-density pheochromocytoma on CT: a mimicker of adrenal 
adenoma. AJR Am J Roentgenol. 2003;181(6):1663-1668. 
19. Jun JH, Ahn HJ, Lee SM, Kim JA, Park BK, Kim JS, Kim JH. Is Preoperative 
Biochemical Testing for Pheochromocytoma Necessary for All Adrenal Incidentalomas? 
Medicine. 2015;94(45). 
20. Buitenwerf E, Korteweg T, Visser A, Haag CMSC, Feelders RA, Timmers HJLM, 
Canu L, Haak HR, Bisschop PHLT, Eekhoff EMW, Corssmit EPM, Krak NC, Rasenberg E, 
van den Bergh J, Stoker J, Greuter MJW, Dullaart RPF, Links TP, Kerstens MN. Unenhanced 
CT imaging is highly sensitive to exclude pheochromocytoma: a multicenter study. Eur J 
Endocrinol. 2018. 
21. Eisenhofer G, Pacak K, Huynh TT, Qin N, Bratslav ky G, Linehan WM, Mannelli M, 
Friberg P, Grebe SK, Timmers HJ, Bornstein SR, Lenders JW. Catecholamine metabolomic 
and secretory phenotypes in phaeochromocytoma. Endocr Relat Cancer. 2011;18(1):97-111. 
22.  Canu L, Van Hemert JAW., Kerstens M, Hartman RP, Khanna A., Kraljevic I, 
Kastelan D, Badiu C, Ambroziak U, Tabarin A, Haissaguerre M, Buitenwerf E, Visser A, 
Mannelli M, Arlt W, Chortis V, Bourdeau I, Gagnon N , Buchy M, Borson-Chazot F, 
Deutschbein T, Fassnacht M, Hubalewska Dydejczy H. A , Motyka M, Rzepka E, Casey R T, 
Challis B G, Quinkler M, Vroonen L, Spyroglou A, Beuschlein F, Lamas C, Young W F, 
Bancos I, Timmers H J L M. Canu_SupdataTab1.pdf. 
https://doi.org/10.6084/m9.figshare.7159688.v1 
23. Hasassri ME, Pandian TK, Bobr AA, Bancos I, Young WF Jr, Richards ML, Farley 
DR, Thompson GB, McKenzie TJ. Pheochromocytoma withSynchronous Ipsilateral Adrenal 
Cortical Adenoma. World J Surg. 2017;41(12):3147-3153. 
24.   Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Pheochr mocytoma as a frequent false-
positive in adrenal washout CT: A systematic review and meta-analysis. Eur Radiol. 2017; 
28(3)1027-1036. 
25.  Cropp RJ, Seslija P, Tso D, Thakur Y. Scanner a d kVp dependence of measured CT 
numbers in the ARC CT phantom. J Appl Clin Med Phys. 2013; 14(6): 4417.  










































































The Journal of Clinical Endocrinology & Metabolism; Copyright 2018  DOI: 10.1210/jc.2018-01532 
 
 9
Figure 2: CT characteristics of PCCs. NA, not available; high washout, absolute ≥60% and/or 
relative ≥40%; low washout, absolute <60% and/or relative <40%.  
Table 1: Characteristics of patients (n=368) and lesions (n=382) of whom quantitative CT 
characteristics were available 
Sex: male (%) 163 (44,2%)  
Age at diagnosis: mean±SD (y)  54,01± 15,05  
Biochemical phenotype: n (%)  
Adrenergic  200 (54,3%)  
Noradrenergic  111 (30,1%)  
Normal values  18 (4,8%)  
Unknown  39 (10,5%)  
Hereditary syndrome: n (%)  60 (16,3%) * 
Maximum diameter: mean±SD  (mm) 42.73±21.96 (n= 306) 
Unenhanced attenuation mean±SD  (HU) 35.04± 10.95 (n= 375) 
* RET (n=32), VHL (n=11), NF1 (n=11), SDHB (n=2), SDHD (n=2), MAX (n=1) and SDHAF2 (n=1) 
Table 2: CT protocols and availability of quantitative data from radiological reports for PCCs 
 
  
CT scan protocol, nr %) 
 Unenhanced  Unenhanced and 
post-contrast  
Contrast washout Unknown  





















only 298 (54,4) 
55 (58,5) 40 (34,2) 24 (16,2) 179 (94,7)  
Unenhanced HU 
and APW/RPW 
78 (14,2)     77 (52,0) 1 (0,5) 
APW/RPW only 6 (1,1)     6 (4,1)   
None 166 (30,3) 39 (41,5) 77 (65,8) 41(27,7) 9 (4,8) 
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